Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic ...

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

B Health and two hospitals seek to intervene in Eli Lilly lawsuit, saying proposed rebate model would burden hospitals with ...

AstraZeneca cuts UK investment after government reduces site expansion support; Viking secures API supply; Jabil acquires ...

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

Progyny acquires BenefitBump and Teladoc buys Catapult Health for $65M, as digital health companies engage in dealmaking.

AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...